
Bristol Myers Bets Billions on Chinese-Discovered Antibody for Cancer
A groundbreaking multi-billion-dollar licensing deal between Germany’s BioNTech SE and U.S. pharmaceutical giant Bristol Myers Squibb (BMS) for a novel cancer therapy is drawing attention to the drug’s origins in China, where it was initially developed and …